A Study to Evaluate the PK, Safety and Tolerability of HCP1803.

NCT05723549 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: HCP1803-3
DRUG: RLD2002
DRUG: HCP1904-1

Sponsor

Hanmi Pharmaceutical Company Limited